Search results for "limination"

showing 10 items of 124 documents

Exploring the Chemoselectivity towards Cysteine Arylation by Cyclometallated Au III Compounds: New Mechanistic Insights

2020

To gain more insight into the factors controlling the efficient cysteine arylation by cyclometalated Au(III) complexes, the reaction between selected gold compounds and different peptides was investigated by high‐resolution liquid chromatography electrospray ionization mass spectrometry (HR‐LC‐ESI‐MS). The deducted mechanisms of C–S cross‐coupling, also supported by density functional theory (DFT) and quantum mechanics/molecular mechanics (QM/MM) calculations, evidenced the key role of secondary peptidic gold binding sites in favouring the process of reductive elimination.

010405 organic chemistryChemistryElectrospray ionizationOrganic Chemistrycyclometallated gold complexes010402 general chemistryMass spectrometry01 natural sciencesBiochemistryCombinatorial chemistryMolecular mechanicsReductive elimination0104 chemical sciencesddc:cysteine arylationGold CompoundschemoselectivitySettore CHIM/03 - Chimica Generale E InorganicapeptidesMolecular MedicineDensity functional theoryChemoselectivityMolecular BiologyCysteinemass spectrometry
researchProduct

Exploring species-level taxonomy in the Cryptocephalus flavipes species complex (Coleoptera: Chrysomelidae)

2016

In insects, morphological species identification is often challenging. The discrimination of closely related species may be hampered when only subtle differences in phenotypic characters or a continuum in their variability are present. This is exemplified in the Cryptocephalus flavipes species complex (Coleoptera; Chrysomelidae) where, until now, the species have been discriminated only by the yellow pattern on frons, pronotum, and epipleurae. In the present study, the phylogeny of the C. flavipes species complex was resolved through a multi-locus sequence approach, and the inclusion in the group of the phenotypically similar Cryptocephalus quadripustulatus Gyllenhal, 1813 was evaluated. Su…

0106 biological sciences0301 basic medicineSpecies complexgeometric morphometricZoologyCryptocephalus quadripustulatus010603 evolutionary biology01 natural sciencesnew ISS rRNA PCR primers03 medical and health sciencesNew 18SrRNA PCR primerSpecies levelPhylogeneticsSpecies delimitationLeaf beetleDNA taxonomyEcology Evolution Behavior and SystematicsTaxonomybiologyBiodiversitybiology.organism_classificationCryptocephalus flavipes030104 developmental biologyTaxonspecies deliminationAnimal Science and ZoologyTaxonomy (biology)Leaf beetleZoological Journal of the Linnean Society
researchProduct

Measles in Italy: Viral strains and crossing borders

2019

In 2017, Italy experienced one of the largest outbreaks of measles in recent years, with 5404 notified cases and 4347 confirmed cases. A further 2029 cases were notified during the first 6 months of 2018, and 1516 of them were laboratory-confirmed. The B3 and D8 genotypes were identified as those responsible for the outbreak. Possible transmission routes can be established by monitoring the circulating measles virus strains in support of the national health authorities to warn people and travellers. Keywords: Outbreak, Measles, Genotype identification, Surveillance

0301 basic medicineGenotyping TechniquesWHO/EuropeSettore MED/42 - Igiene Generale E ApplicataDisease OutbreaksWHO0302 clinical medicineMeasleGenotype030212 general & internal medicineTravelSurveillancebiologyTransmission (medicine)General MedicineEmigration and ImmigrationInfectious DiseasesGenotype identificationItalyWorld Health Organization European RegionSequence AnalysisMicrobiology (medical)medicine.medical_specialtyGenotype030106 microbiologyWorld Health OrganizationMeasleslcsh:Infectious and parasitic diseasesEuropean Regional Verification Commission for Measles and Rubella Elimination; Genotype identification; MeaNS; Measles; Measles Nucleotide Surveillance; Outbreak; RVC; Surveillance; WHO; WHO/Europe; World Health Organization; World Health Organization European RegionOutbreak Measles Genotype identification SurveillanceMeasles virus03 medical and health sciencesGenotype identification; Measles; Outbreak; Surveillance; Emigration and Immigration; Genotype; Genotyping Techniques; Humans; Italy; Measles; Measles virus; Sequence Analysis DNA; Travel; Disease OutbreaksmedicineHumanslcsh:RC109-216Genotyping TechniquesMeaNSNational healthEuropean Regional Verification Commission for Measles and Rubella EliminationPublic healthOutbreakOutbreakSequence Analysis DNADNAmedicine.diseasebiology.organism_classificationVirologyRVCMeasles virusMeasles Nucleotide SurveillanceMeasles
researchProduct

Oleoylethanolamide restores alcohol-induced inhibition of neuronal proliferation and microglial activity in striatum

2019

Previous findings demonstrate a homeostatic role for oleoylethanolamide (OEA) signaling in the ethanol-related neuroinflammation and behavior. However, extensive research is still required in order to unveil the effects of OEA on a number of neurobiological functions such as adult neurogenesis, cell survival and resident neuroimmunity that become notably altered by alcohol. Daily consumption of ethanol (10%) for 2 weeks (6.3& #x202F;± 1.1 g/kg/day during last 5 days) caused hypolocomotor activity in rats. This effect appears to rely on central signaling mechanisms given that alcohol increased the OEA levels, the gene expression of OEA-synthesizing enzyme Nape-pld and the number of PPARα-imm…

0301 basic medicineMaleApoptosisOleic AcidsStriatumPPARαOleoylethanolamidechemistry.chemical_compound0302 clinical medicineNeuronseducation.field_of_studyCaspase 3NeurogenesisMicrofilament ProteinsAlanine Transaminasegamma-GlutamyltransferaseHepatobiliary EliminationEthanolaminesMicrogliaAlcoholProto-Oncogene Proteins c-fosLocomotionFOSBSignal Transductionmedicine.medical_specialtyAlcohol DrinkingCell SurvivalPolyunsaturated AlkamidesNeurogenesisPopulationCaspase 3Arachidonic AcidsStriatumAmidohydrolases03 medical and health sciencesCellular and Molecular NeuroscienceInternal medicineGlial Fibrillary Acidic ProteinmedicinePhospholipase DAnimalsPPAR alphaAspartate AminotransferasesProgenitor cellRats WistareducationNeuroinflammationCell ProliferationPharmacologyEthanolCalcium-Binding ProteinsRatsNeostriatum030104 developmental biologyEndocrinologychemistry030217 neurology & neurosurgeryEndocannabinoids
researchProduct

Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8 Weeks’ Glecaprevir/Pibrentasvir Therapy

2021

Introduction: In Italy, hepatitis C virus (HCV) elimination is achievable; however, barriers remain to achieving the World Health Organization's elimination targets, and have become more pronounced with the spread of COVID-19. Glecaprevir/pibrentasvir (G/P) is a direct-acting antiviral therapy for HCV, approved for 8-week treatment in patients without cirrhosis, and with compensated cirrhosis (CC). Previously, 12 weeks of therapy was recommended for patients with CC. Shortened treatment may reduce the burden on healthcare resources, allowing more patients to be treated. This study presents the benefits that 8-week vs 12-week treatment with G/P may have in Italy. Methods: A multicohort Marko…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)EliminationTreatment duration030106 microbiologyPopulationTreatment duration03 medical and health sciences0302 clinical medicineHealth careTreatment duration.Medicine030212 general & internal medicineeducationOriginal ResearchHepatitis C viruseducation.field_of_studyGlecaprevir/pibrentasvirbusiness.industryGlecaprevirPibrentasvirInfectious DiseasesItalyEmergency medicineObservational studyGlecaprevir / pibrentasvirHepatitis C virubusinessInfectious Diseases and Therapy
researchProduct

Impact of COVID-19 on global HCV elimination efforts.

2021

Background & Aims COVID-19 has placed significant strain on national healthcare systems at a critical moment in the context of hepatitis elimination. Mathematical models can be used to evaluate the possible impact of programmatic delays on hepatitis disease burden. The objective of this analysis was to evaluate the incremental change in hepatitis C liver-related deaths and liver cancer, following a 3-month, 6-month, or 1-year hiatus in hepatitis elimination program progress. Methods Previously developed models were adapted for 110 countries to include a status quo or “no delay” scenario and a “1-year delay” scenario assuming significant disruption in interventions (screening, diagnosis and …

0301 basic medicinePsychological interventioncoronavirusUMIC upper-middle income countriesGlobal HealthUI uncertainty intervalHIC high income countries0302 clinical medicineCost of IllnessLIC low income countriesMedicineUSA United States of AmericaLetter to the EditorMathematical modellingPWID people who inject drugsLiver DiseaseLiver DiseasesVaccinationmathematical modelingGBD Global Burden of DiseaseHepatitis CSVR sustained virologic responseEuropeHCV hepatitis C virusHepatocellular carcinomaHCVGHSS Global Health Sector StrategyRNA Viral030211 gastroenterology & hepatologyAMR region of the AmericasLiver cancerViral hepatitisHumanCarcinoma HepatocellularCoronavirus disease 2019 (COVID-19)EMR Eastern Mediterranean regionViral hepatitis eliminationviral hepatitisContext (language use)World Health OrganizationArticleWHO World Health OrganizationTime-to-Treatment03 medical and health scienceseliminationEnvironmental healthHumansLMIC lower-middle income countriesDisease EradicationDisease burdenHepatitisHepatologySARS-CoV-2business.industryWPR Western Pacific regionCOVID-19Models Theoreticalmedicine.diseaseCost of Illne030104 developmental biologySpainHCC hepatocellular carcinomabusinessJournal of hepatology
researchProduct

Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways.

2021

The availability of pangenotypic direct-acting antivirals for treatment of hepatitis C (HCV) has provided an opportunity to simplify patient pathways. Recent clinical practice guidelines have recognised the need for simplification to ensure that elimination of HCV as a public health concern remains a priority. Despite the move towards simplified treatment algorithms, there remains some complexity in the recommendations for the management of genotype 3 patients with compensated cirrhosis. In an era where additional clinical trial data are not anticipated, clinical guidance should consider experience gained in real-world settings. Although more experience is required for some pangenotypic the…

030213 general clinical medicinemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)EliminationGuidelineGuidelinesGlobal HealthAntiviral AgentsPatient pathwaySimplification03 medical and health sciences0302 clinical medicinePandemicGlobal healthMedicineHumansPharmacology (medical)Disease EradicationIntensive care medicineAntiviral Agentbusiness.industrySARS-CoV-2Public healthCOVID-19General MedicineHepatitis CHcv eliminationClinical trialCritical Pathway030220 oncology & carcinogenesisCommunicable Disease ControlPractice Guidelines as TopicKey (cryptography)Critical PathwaysCommentarybusinessHumanAdvances in therapy
researchProduct

La patria potestad prorrogada y la patria potestad rehabilitada en el nuevo proyecto de ley de reforma de la legislación civil y procesal para el apo…

2021

It is intended to analyze and reflect in the present work about the institution of the extension of parental authority and parental authority rehabilitated in the new regulation in the Draft Law that reforms the civil and procedural legislation to support people with disabilities in the exercise of their legal capacity. In this project, the extended parental authority and the rehabilitated parental authority are eliminated from the scope of disability, following a criterion that demands the treatment of people with disabilities with the attention that their specific situation requires, eliminating a regime that seems contrary to the system of promoting the autonomy of adults with disabiliti…

:CIENCIAS JURÍDICAS [UNESCO]parental authorityrehabilitacióneliminating a regime that seems contrary to the system of promoting the autonomy of adults with disabilities. This study is linked and addressedas they will be affected by the reform and by the effect of the structural deficiencies suffered by the Justice system of our country. the present work about the institution of the extension of parental authority and parental authority rehabilitated in the new regulation in the Bill of Law that reforms the civil and procedural legislation to support people with disabilities in the exercise of its legal capacity. In this projectelimination 236 251eliminaciónrehabilitationPablo It is intended to analyze and reflect in the present work about the institution of the extension of parental authority and parental authority rehabilitated in the new regulation in the Draft Law that reforms the civil and procedural legislation to support people with disabilities in the exercise of their legal capacity. In this projectprojectproyectoUNESCO::CIENCIAS JURÍDICASthe extended parental authority and the rehabilitated parental authority are eliminated from the scope of disabilitypatria potestadExtensionwith the characteristics and needs of people with a severe intellectual disabilityas they will be affected by the reform and by the effect of the structural insufficiencies suffered by the Justice system of our country. Prórroga2070-8157 22082 Revista Boliviana de Derecho 584568 2021 32 8055222 La patria potestad prorrogada y la patria potestad rehabilitada en el nuevo proyecto de ley de reforma de la legislación civil y procesal para el apoyo a las personas con discapacidad (actual ley 8/2021) Tortajada Chardífollowing a criterion that demands the treatment of people with disabilities with the attention that their specific situation requireshealth care economics and organizations
researchProduct

The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four European countries

2021

Eliminació del VHC; Punt d'equilibri; Infecció d'hepatitis C Eliminación del VHC; Punto de equilibrio; Infección de hepatitis C HCV elimination; Break-even; Hepatitis C infection Background and Aims We assessed the clinical and economic impact of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) in England, Italy, Romania and Spain. Methods An HCV progression Markov model was developed considering DAA eligibility and population data during the years 2015-2019. The period of time to recover the investment in DAAs was calculated as the cost saved by avoiding estimated clinical events for 1000 standardized treated patients. A delayed treatment scenario because of coronavirus di…

:Health Care Economics and Organizations::Economics::Costs and Cost Analysis::Cost Control::Cost Savings [HEALTH CARE]DiseaseHepacivirusmedicine.disease_cause:Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis Viral Human::Hepatitis C [DISEASES]0302 clinical medicineCost of IllnessMedicine:Other subheadings::/therapeutic use [Other subheadings]Economic impact analysisChronicExit strategyevenLiver NeoplasmsHealth services researchhealthInvestment (macroeconomics)Hepatitis C:Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents [CHEMICALS AND DRUGS]break‐EnglandItalyHCV elimination030220 oncology & carcinogenesisOriginal Article030211 gastroenterology & hepatologyLiver Disease and Public HealthHumanHepatitis C virusSettore SECS-P/03hepatitis C infectionMedicaments antivírics- Ús terapèuticAntiviral AgentsTime-to-Treatment03 medical and health sciencesbreak-evenHumansbusinessDisease burdenDAAAntiviral Agent:economía y organizaciones para la atención de la salud::economía::costes y análisis de costes::control de costes::ahorro de costes [ATENCIÓN DE SALUD]HepaciviruHepatology:Otros calificadores::/uso terapéutico [Otros calificadores]business.industryRomania:enfermedades del sistema digestivo::enfermedades hepáticas::hepatitis::hepatitis viral humana::hepatitis C [ENFERMEDADES]COVID-19break‐evenDAAsHepatitis C ChronicEstalvi i inversióHcv eliminationCost of IllneSpain:acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos [COMPUESTOS QUÍMICOS Y DROGAS]Communicable Disease ControlVirus de l'hepatitis CbusinessDemography
researchProduct

Polyoxypregnanes as safe, potent, and specific ABCB1-inhibitory pro-drugs to overcome multidrug resistance in cancer chemotherapy in vitro and in vivo

2021

Multidrug resistance (MDR) mediated by ATP binding cassette subfamily B member 1 (ABCB1) is significantly hindering effective cancer chemotherapy. However, currently, no ABCB1-inhibitory drugs have been approved to treat MDR cancer clinically, mainly due to the inhibitor specificity, toxicity, and drug interactions. Here, we reported that three polyoxypregnanes (POPs) as the most abundant constituents of Marsdenia tenacissima (M. tenacissima) were novel ABCB1-modulatory pro-drugs, which underwent intestinal microbiota-mediated biotransformation in vivo to generate active metabolites. The metabolites at non-toxic concentrations restored chemosensitivity in ABCB1-overexpressing cancer cells v…

ABCC1 ATP binding cassette subfamily C member 1IC50 half maximal inhibitory concentrationMultidrug resistancePharmacologyNADPH reduced nicotinamide adenine dinucleotide phosphateF bioavailabilitychemistry.chemical_compoundPCR polymerase chain reaction0302 clinical medicineMDR multidrug resistanceECL electrochemiluminescencet1/2 elimination half-lifeLC–MS liquid chromatography coupled with mass spectrometryN.D. not detectedGeneral Pharmacology Toxicology and PharmaceuticsBBB blood–brain barriermedia_commonATF3 activating transcription factor 30303 health sciencesChemistryABC ATP-binding cassetteNMPA National Medical Products AdministrationPXR pregnane X receptorSDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresisHBSS Hankʹs balanced salt solutionABCB1Combination chemotherapyProdrugMarsdenia tenacissimaCmax peak concentrationPaclitaxelGAPDH glyceraldehyde-3-phosphate dehydrogenase030220 oncology & carcinogenesisBHI brain heart infusionOriginal ArticleAUC0–∞ area under plasma concentration vs. time curveMRT mean residence timeDrugmedia_common.quotation_subjectRM1-950Vd volume of distributionABCB1 ATP binding cassette subfamily B member 1UIC-2 mouse monoclonal ABCB1 antibodyABCG2 ATP binding cassette subfamily G member 2Combination chemotherapyCYP cytochrome P450 isozymePI propidium iodideTEER transepithelial electrical resistance03 medical and health sciencesPBS phosphate buffer salineFBS fetal bovine serumDox doxorubicinIn vivoPOP polyoxypregnanemedicine030304 developmental biologyEVOM epithelial tissue voltohmmeterTmax time for peak concentrationCancerLBE lowest binding energyPE phycoerythrinmedicine.diseaseMultiple drug resistancePolyoxypregnanePapp apparent permeabilityN.A. not applicableCancer cellH&E hematoxylin and eosinMDR1a multidrug resistance protein 1aTherapeutics. PharmacologyqPCR quantitative PCRM. tenacissima Marsdenia tenacissimaCL clearanceSD standard derivationActa Pharmaceutica Sinica B
researchProduct